{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:47:53Z","timestamp":1758815273571},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,9,24]],"date-time":"2008-09-24T00:00:00Z","timestamp":1222214400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mortality among HIV-infected children in developing countries remains high after serious bacterial infections despite the use of antibiotics. Intravenous immunoglobulin (IVIG) has been used as an adjuvant therapy to treat these infections, but little data exists regarding its efficacy, and previous studies have focused on IVIG as a prophylactic agent. We examined the impact of IVIG as an adjuvant therapy in reducing mortality and length of hospital stay in HIV-infected children with serious bacterial infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study focused on pediatric admissions at a large urban hospital between 2002 and 2006. Children between the ages of one month and nine years of age with laboratory confirmed HIV-status, serious bacterial infection, no prior exposure to IVIG, and a hospital length of stay of 5 days or more, were eligible for inclusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 140 children (median age 1.2 years) met inclusion criteria; lower respiratory tract infection was diagnosed in 94 (67%) of the children, while 74 (53%) had bacterial sepsis. Fifty-four (39%) children were receiving antiretroviral therapy and 39 (28%) were receiving tuberculosis treatment. Overall 73 (52%) were treated with IVIG, with the majority (74%) of children receiving a single dose. Thirteen (9%) died during their hospital admission. In crude analysis IVIG was significantly associated with increased mortality was (Odds Ratio (OR): 5.8; 95% Confidence Interval (CI): 1.2\u201327.1) and this association was weakened by adjustment for other predictors of mortality (OR 4.3, 95% CI 0.7\u201327.9, p = 0.123). IVIG use was also associated with longer hospital stays.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Administration of one to three doses of IVIG during the acute phase of illness does not appear to reduce mortality or the length of hospital stays in HIV-infected children with serious bacterial infections. However, the retrospective nature of this study makes confounding by indication difficult to control and further studies regarding the timing, dosing, and method of administration are required. Nonetheless the routine use of IVIG in resource-limited settings should be carefully considered given its high cost.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-8-127","type":"journal-article","created":{"date-parts":[[2008,9,24]],"date-time":"2008-09-24T06:13:58Z","timestamp":1222236838000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: A retrospective cohort study"],"prefix":"10.1186","volume":"8","author":[{"given":"Lyen C","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon","family":"Myer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather B","family":"Jaspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,24]]},"reference":[{"key":"718_CR1","volume-title":"UNAIDS\/WHO AIDS Epidemic Update: December 2006","author":"UNAIDS\/WHO","year":"2006","unstructured":"UNAIDS\/WHO: UNAIDS\/WHO AIDS Epidemic Update: December 2006. 2006, Geneva, Switzerland: UNAIDS\/WHO, [http:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/EpiUpdate\/EpiUpdArchive\/2006\/Default.asp]"},{"key":"718_CR2","volume-title":"National HIV and Syphilis Antenatal Sero-prevalence Survey in South Africa 2005","author":"South African Department of Health","year":"2005","unstructured":"South African Department of Health: National HIV and Syphilis Antenatal Sero-prevalence Survey in South Africa 2005. 2005, Pretoria: South African Department of Health, [http:\/\/www.doh.gov.za\/docs\/reports\/2005\/hiv.pdf]"},{"key":"718_CR3","first-page":"202","volume":"94","author":"A Krug","year":"2004","unstructured":"Krug A, Pattinson RC, Power DJ: Why children die: an under-5 health care survey in Mafikeng region. S Afr Med J. 2004, 94: 202-206.","journal-title":"S Afr Med J"},{"key":"718_CR4","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1097\/00002030-199816000-00013","volume":"12","author":"N Jones","year":"1998","unstructured":"Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K: The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS. 1998, 12: 2177-2184. 10.1097\/00002030-199816000-00013.","journal-title":"AIDS"},{"key":"718_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1086\/313925","volume":"31","author":"SA Madhi","year":"2000","unstructured":"Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP: Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2000, 31: 170-176. 10.1086\/313925.","journal-title":"Clin Infect Dis"},{"key":"718_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/tropej\/46.4.224","volume":"46","author":"TM Meyers","year":"2000","unstructured":"Meyers TM, Pettifor JM, Gray GE, Crewe-Brown H, Galpin JS: Pediatric admissions with human immunodeficiency virus infection at a regional hospital in Soweto, South Africa. J Trop Pediatr. 2000, 46: 224-230. 10.1093\/tropej\/46.4.224.","journal-title":"J Trop Pediatr"},{"key":"718_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000093204","volume":"140","author":"A Kumar","year":"2006","unstructured":"Kumar A, Teuber SS, Gershwin ME: Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol. 2006, 140: 185-198. 10.1159\/000093204.","journal-title":"Int Arch Allergy Immunol"},{"key":"718_CR8","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/WNL.59.12_suppl_6.S13","volume":"59","author":"MC Dalakas","year":"2002","unstructured":"Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002, 59: S13-S21.","journal-title":"Neurology"},{"key":"718_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molimm.2004.07.046","volume":"42","author":"R Lemieux","year":"2005","unstructured":"Lemieux R, Bazin R, N\u00e9ron S: Therapeutic intravenous immunoglobulins. Mol Immunol. 2005, 42: 839-848. 10.1016\/j.molimm.2004.07.046.","journal-title":"Mol Immunol"},{"key":"718_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199107113250201","volume":"325","author":"NICHD","year":"1991","unstructured":"NICHD: Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med. 1991, 325: 73-80.","journal-title":"N Engl J Med"},{"key":"718_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJM199411033311802","volume":"331","author":"SA Spector","year":"1994","unstructured":"Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM: A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994, 331: 1181-1187. 10.1056\/NEJM199411033311802.","journal-title":"N Engl J Med"},{"key":"718_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/tropej\/fmi011","volume":"51","author":"A El-Nawawy","year":"2005","unstructured":"El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N: Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005, 51: 271-278. 10.1093\/tropej\/fmi011.","journal-title":"J Trop Pediatr"},{"key":"718_CR13","first-page":"CD001239","volume-title":"Cochrane Database Syst Rev","author":"A Ohlsson","year":"2004","unstructured":"Ohlsson A, Lacy JB: Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004, CD001239-"},{"key":"718_CR14","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1542\/peds.99.2.e2","volume":"99","author":"HB Jenson","year":"1997","unstructured":"Jenson HB, Pollock BH: Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics. 1997, 99: E2-10.1542\/peds.99.2.e2.","journal-title":"Pediatrics"},{"key":"718_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/421089","volume":"39","author":"J Pildal","year":"2004","unstructured":"Pildal J, G\u00f8tzsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004, 39: 38-46. 10.1086\/421089.","journal-title":"Clin Infect Dis"},{"key":"718_CR16","first-page":"CD001090","volume-title":"Cochrane Database Syst Rev","author":"MM Alejandria","year":"2002","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring JB: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002, CD001090-"},{"key":"718_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1081-1206(10)62563-X","volume":"85","author":"ER Stiehm","year":"2000","unstructured":"Stiehm ER: Shortage of IV immunoglobulin. Ann Allergy Asthma Immunol. 2000, 85: 424-","journal-title":"Ann Allergy Asthma Immunol"},{"key":"718_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1081-1206(10)62792-5","volume":"81","author":"H Milgrom","year":"1998","unstructured":"Milgrom H: Shortage of intravenous immunoglobulin. Ann Allergy Asthma Immunol. 1998, 81: 97-100.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"718_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00003246-199605000-00004","volume":"24","author":"MM Pollack","year":"1996","unstructured":"Pollack MM, Patel KM, Ruttimann UE: PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996, 24: 743-752. 10.1097\/00003246-199605000-00004.","journal-title":"Crit Care Med"},{"key":"718_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1067\/mai.2000.109433","volume":"106","author":"WT Shearer","year":"2000","unstructured":"Shearer WT, Easley KA, Goldfarb J, Rosenblatt HM, Jenson HB, Kovacs A, McIntosh K: Prospective 5-year study of peripheral blood CD4, CD8, and CD19\/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group. J Allergy Clin Immunol. 2000, 106: 559-566. 10.1067\/mai.2000.109433.","journal-title":"J Allergy Clin Immunol"},{"key":"718_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00007611-199902000-00009","volume":"92","author":"CA Arango","year":"1999","unstructured":"Arango CA, Midani S, Alvarez A, Kubilis PS, Rathore MH: Usefulness of acute phase reactants in the diagnosis of acute infections in HIV-infected children. South Med J. 1999, 92: 209-213. 10.1097\/00007611-199902000-00009.","journal-title":"South Med J"},{"key":"718_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/ije\/28.2.341","volume":"28","author":"P Waibale","year":"1999","unstructured":"Waibale P, Bowlin SJ, Mortimer EA, Whalen C: The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol. 1999, 28: 341-346. 10.1093\/ije\/28.2.341.","journal-title":"Int J Epidemiol"},{"key":"718_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/00006454-199612000-00008","volume":"15","author":"D Gibb","year":"1996","unstructured":"Gibb D, Giacomelli A, Masters J, Spoulou V, Ruga E, Griffiths H, Kroll S, Giaquinto C, Goldblatt D: Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J. 1996, 15: 1097-1101. 10.1097\/00006454-199612000-00008.","journal-title":"Pediatr Infect Dis J"},{"key":"718_CR24","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1086\/379900","volume":"188","author":"HM Lederman","year":"2003","unstructured":"Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts NJ, Currier JS, AIDS Clinical Trials Group 889 Study Team: Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis. 2003, 188: 1794-1803. 10.1086\/379900.","journal-title":"J Infect Dis"},{"key":"718_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1592\/phco.26.6.813","volume":"26","author":"T Koleba","year":"2006","unstructured":"Koleba T, Ensom MH: Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006, 26: 813-827. 10.1592\/phco.26.6.813.","journal-title":"Pharmacotherapy"},{"key":"718_CR26","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1203\/00006450-199333011-00015","volume":"33","author":"LM Mofenson","year":"1993","unstructured":"Mofenson LM, Moye J: Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection. Pediatr Res. 1993, 33: S80-7. 10.1203\/00006450-199304001-00015. discussion S87-9","journal-title":"Pediatr Res"},{"key":"718_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2334-7-43","volume":"7","author":"B Blomberg","year":"2007","unstructured":"Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, Msangi V, Tellevik MG, Holberg-Petersen M, Harthug S, Maselle SY, Langeland N: Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis. 2007, 7: 43-10.1186\/1471-2334-7-43.","journal-title":"BMC Infect Dis"},{"key":"718_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00005176-200105000-00011","volume":"32","author":"B Amadi","year":"2001","unstructured":"Amadi B, Kelly P, Mwiya M, Mulwazi E, Sianongo S, Changwe F, Thomson M, Hachungula J, Watuka A, Walker-Smith J, Chintu C: Intestinal and systemic infection, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. J Pediatr Gastroenterol Nutr. 2001, 32: 550-554. 10.1097\/00005176-200105000-00011.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"718_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/02724930092075","volume":"20","author":"L Kessler","year":"2000","unstructured":"Kessler L, Daley H, Malenga G, Graham S: The impact of the human immunodeficiency virus type 1 on the management of severe malnutrition in Malawi. Ann Trop Paediatr. 2000, 20: 50-56. 10.1080\/02724930092075.","journal-title":"Ann Trop Paediatr"},{"key":"718_CR30","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0040045","volume":"4","author":"GT Heikens","year":"2007","unstructured":"Heikens GT: How can we improve the care of severely malnourished children in Africa?. PLoS Med. 2007, 4: e45-10.1371\/journal.pmed.0040045.","journal-title":"PLoS Med"},{"key":"718_CR31","first-page":"237","volume":"81","author":"JL Deen","year":"2003","unstructured":"Deen JL, Funk M, Guevara VC, Saloojee H, Doe JY, Palmer A, Weber MW: Implementation of WHO guidelines on management of severe malnutrition in hospitals in Africa. Bull World Health Organ. 2003, 81: 237-243.","journal-title":"Bull World Health Organ"},{"key":"718_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","volume":"21","author":"A Gardulf","year":"2007","unstructured":"Gardulf A: Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007, 21: 105-116. 10.2165\/00063030-200721020-00005.","journal-title":"BioDrugs"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-8-127\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-8-127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:33:07Z","timestamp":1630488787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-8-127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-8-127","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,24]]},"assertion":[{"value":"7 March 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"127"}}